Assessing 4DMedical (ASX:4DX) Valuation After Expanded CT:VQ Partnership With University Of Chicago Medicine

Simply Wall St.

Feb 04

AdvertisementWhy 4DMedical Shares Are Back in Focus 4DMedical (ASX:4DX) is back on investor radars after expanding its partnership with University of Chicago Medicine to include commercial deployment ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608367835"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608367835\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608367835?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","is_english":true,"pubTime":"2026-02-04 18:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608367835","market":"sg","top_or_hot":-1,"title":"Assessing 4DMedical (ASX:4DX) Valuation After Expanded CT:VQ Partnership With University Of Chicago Medicine","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy 4DMedical Shares Are Back in Focus 4DMedical (ASX:4DX) is back on investor radars after expanding its partnership with University of Chicago Medicine to include commercial deployment ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/assessing-4dmedical-asx4dx-valuation-after-expanded-ctvq-par\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing 4DMedical (ASX:4DX) Valuation After Expanded CT:VQ Partnership With University Of Chicago Medicine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing 4DMedical (ASX:4DX) Valuation After Expanded CT:VQ Partnership With University Of Chicago Medicine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-04 18:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/assessing-4dmedical-asx4dx-valuation-after-expanded-ctvq-par><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy 4DMedical Shares Are Back in Focus 4DMedical (ASX:4DX) is back on investor radars after expanding its partnership with University of Chicago Medicine to include commercial deployment ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/assessing-4dmedical-asx4dx-valuation-after-expanded-ctvq-par\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7094","symbol_name":"医疗保健技术","start_time":0,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/assessing-4dmedical-asx4dx-valuation-after-expanded-ctvq-par","article_id":"2608367835","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-4dx/4dmedical-shares/news/assessing-4dmedical-asx4dx-valuation-after-expanded-ctvq-par","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2608367835","pubTimestamp":1770200558,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why 4DMedical Shares Are Back in Focus\n4DMedical (ASX:4DX) is back on investor radars after expanding its partnership with University of Chicago Medicine to include commercial deployment of its CT:VQ respiratory imaging technology.\nSee our latest analysis for 4DMedical.\nThe commercial CT:VQ rollout headlines a period where 4DMedical’s 90 day share price return of about 131% contrasts sharply with a 26% decline year to date, while its one year total shareholder return is very large at over...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7094":"医疗保健技术","4DX.AU":"4DMEDICAL LTD"},"translate_title":"与芝加哥大学医学院扩大CT：VQ合作伙伴关系后评估4DMedical(ASX：4DX)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"4DX.AU":1.5},"content_text":"AdvertisementWhy 4DMedical Shares Are Back in Focus 4DMedical (ASX:4DX) is back on investor radars after expanding its partnership with University of Chicago Medicine to include commercial deployment of its CT:VQ respiratory imaging technology. See our latest analysis for 4DMedical. The commercial CT:VQ rollout headlines a period where 4DMedical’s 90 day share price return of about 131% contrasts sharply with a 26% decline year to date, while its one year total shareholder return is very large at over 6x. If this kind of healthcare tech story interests you, it may be a good moment to see what else is out there through healthcare stocks as another set of ideas to review. With 4DMedical trading close to its A$3.40 analyst price target, after a one year return of more than 6x, you have to ask: is there still value on the table, or is the market already pricing in future growth? Most Popular Narrative: 24% Overvalued At A$3.38, 4DMedical is trading above the most followed narrative fair value of A$2.73, which is built using a 7.81% discount rate.  The development and expected FDA approval of the CT:VQ technology, which offers logistical improvements over current nuclear medicine solutions, present a significant opportunity to capture a share of the $1 billion market, potentially enhancing net margins through the provision of superior cost-saving technology.  Read the complete narrative. Want to understand why this growth story still screens as expensive? The narrative leans on rapid revenue expansion, margin uplift, and a rich future earnings multiple. Curious how those moving parts combine to justify today’s fair value? Result: Fair Value of A$2.73 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, you still need to watch the cash burn and short funding runway, as well as execution risks around new products and the Philips reseller rollout. Find out about the key risks to this 4DMedical narrative.  Build Your Own 4DMedical Narrative If you look at the numbers and come to a different conclusion, that is fine. You can quickly build your own view in minutes, Do it your way. A great starting point for your 4DMedical research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision. Looking for more investment ideas? If 4DMedical has sharpened your interest, do not stop here. Use the screener to spot other opportunities that fit your style before the crowd moves on.  Target dependable income by checking out these 13 dividend stocks with yields > 3% that may suit a portfolio focused on regular cash returns. Back potential early stage growth stories with these 3535 penny stocks with strong financials that already show stronger fundamentals than many of their peers. Position yourself for long term themes through these 19 cryptocurrency and blockchain stocks tied to blockchain, digital payments, and related technologies.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}